Schistosoma haematobium treatment in 1-5 year old children: safety and efficacy of the antihelminthic drug praziquantel.

Mutapi, Francisca and Rujeni, Nadine and Bourke, Claire and Mitchell, Kate and Appleby, Laura and Nausch, Norman and Midzi, Nicholas and Mduluza, Takafira (2011) Schistosoma haematobium treatment in 1-5 year old children: safety and efficacy of the antihelminthic drug praziquantel. e1143. ISSN 1935-2735

Full text not available from this repository.

Abstract

Pre-treatment S. haematobium infection intensity in 1-5 year olds was 14.6 eggs/10 ml urine and prevalence was 21%. Of the 104 children, 3.8% reported side effects within 24 hours of taking PZQ treatment. These were stomach ache, loss of appetite, lethargy and inflammation of the face and body. PZQ treatment significantly reduced schistosome infection levels in 1-5 year olds with an egg reduction rate (ERR) of 99% and cure rate (CR) of 92%. This was comparable to the efficacy of praziquantel in 6-10 year olds where ERR was 96% and CR was 67%. INTERPRETATION/SIGNIFICANCE: PZQ treatment is as safe and efficacious in children aged 1-5 years as it is in older children aged 6-10 years in whom PZQ is the drug of choice for control of schistosome infections.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
Divisions: Universities > State Universities > Midlands State University
Depositing User: Professor Takafira MDULUZA
Date Deposited: 11 Apr 2012 12:17
Last Modified: 11 Apr 2012 12:17
URI: http://researchdatabase.ac.zw/id/eprint/124

Actions (login required)

View Item View Item